A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment

• ClinicalTrials.gov Identifier: NCT04627285
• Recruitment Status: Active, not recruiting
• First Posted: November 13, 2020
• Last Update Posted: August 4, 2022
• Sponsor: UCB Biopharma SRL
• Information provided by (Responsible Party): UCB Pharma ( UCB Biopharma SRL )

Study Description

Brief Summary:

The purpose of the study is to assess the long-term use of lacosamide oral solution dosed at 2 mg/kg/day to 12 mg/kg/day when administered to pediatric study participants with epilepsy who have completed NCT01964560 (EP0034) or NCT00938912 (SP848).

Condition or disease	Intervention/treatment	Phase
Epilepsy	Drug: Lacosamide	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 48 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Multicenter, Open-Label, Follow-Up Study to Assess the Long-Term Use of Oral Lacosamide in Study Participants Who Completed EP0034 or SP848 and Received Lacosamide Treatment
• Actual Study Start Date: December 28, 2020
• Estimated Primary Completion Date: August 2025
• Estimated Study Completion Date: August 2025

Arms and Interventions

Arm	Intervention/treatment
Experimental: Lacosamide; Subjects in this arm will receive various single doses of lacosamide	Drug: Lacosamide; Pharmaceutical form: Oral-solution; Route of administration: Oral use Subjects will receive lacosamide in a pre-specified sequence during the Treatment Period.

Outcome Measures

Primary Outcome Measures :

1. Incidence of treatment-emergent adverse events (TEAEs) [ Time Frame: From visit 1 (Week 0) to the end of study visit (up to Week 213) ]
   An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
2. Withdrawals from study due to TEAEs [ Time Frame: From visit 1 (Week 0) to the end of study visit (up to Week 213) ]
   An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
3. Withdrawals from study due to Serious Adverse Event (SAEs) [ Time Frame: From visit 1 (Week 0) to the end of study visit (up to Week 213) ]
   • Results in death
   • Is life-threatening
   • Requires in patient hospitalization or prolongation of existing hospitalization
   • Is a congenital anomaly or birth defect
   • Is an infection that requires treatment parenteral antibiotics
   • Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above
4. Modal daily dose during the study [ Time Frame: From visit 1 (Week 0) to the end of study visit (up to Week 213) ]
   Modal daily dose, defined as most frequently administered dose per mg/kg/day.
5. Maximum daily dose during the study [ Time Frame: From visit 1 (Week 0) to the end of study visit (up to Week 213) ]
   Maximum daily dose, defined as the highest administered dose per mg/kg/day.

Eligibility Criteria

• Ages Eligible for Study: 2 Years to 5 Years (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Participant is male or female, aged <6 years at the time of signing the Informed Consent Form (ICF)
• Participant has completed participation in NCT01964560 (EP0034) or NCT00938912 (SP848)
• Participant is expected to benefit from participation, in the opinion of the Investigator

Exclusion Criteria:

• Participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study
• Participant has a known hypersensitivity to any components of the study medication or comparative drugs as stated in this protocol
• Participant is receiving any investigational drugs or using any experimental devices in addition to lacosamide (LCM)
• Participant meets a mandatory withdrawal criterion (ie, MUST withdraw criterion) for NCT01964560 (EP0034) or NCT00938912 (SP848), or is experiencing an ongoing serious adverse event (SAE)
• Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates participation in the study

Contacts and Locations

Locations

Georgia

Ep0151 620

Tbilisi, Georgia

Ep0151 621

Tbilisi, Georgia

Ep0151 622

Tbilisi, Georgia

Hungary

Ep0151 361

Budapest, Hungary

Ep0151 362

Budapest, Hungary

Moldova, Republic of

Ep0151 650

Chisinau, Moldova, Republic of

Romania

Ep0151 581

Bucuresti, Romania

Ep0151 582

Iasi, Romania

Ep0151 577

Timisoara, Romania

Taiwan

Ep0151 224

Taipei, Taiwan

Ukraine

Ep0151 609

Dnipropetrovsk, Ukraine

Ep0151 602

Dnipro, Ukraine

Ep0151 606

Kiev, Ukraine

Ep0151 682

Uzhgorod, Ukraine

Ep0151 603

Vinnytsya, Ukraine

Sponsors and Collaborators

UCB Biopharma SRL

Investigators

• Study Director: UCB Cares; 001 844 599 2273 (UCB)

More Information

• Responsible Party: UCB Biopharma SRL
• ClinicalTrials.gov Identifier: NCT04627285
• Other Study ID Numbers: EP0151; 2020-001478-30 ( EudraCT Number )
• First Posted: November 13, 2020
• Last Update Posted: August 4, 2022
• Last Verified: August 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
• Supporting Materials: Study Protocol; Statistical Analysis Plan (SAP); Clinical Study Report (CSR)
• Time Frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
• Access Criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
• URL: https://www.Vivli.org

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by UCB Pharma ( UCB Biopharma SRL ):

Lacosamide; Vimpat; Epilepsy; Pediatric

Additional relevant MeSH terms:

Epilepsy; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Lacosamide; Anticonvulsants; Voltage-Gated Sodium Channel Blockers; Sodium Channel Blockers; Membrane Transport Modulators; Molecular Mechanisms of Pharmacological Action